MDNAF
Price
$0.61
Change
-$0.05 (-7.58%)
Updated
Jun 27 closing price
Capitalization
47.34M
39 days until earnings call
PTCT
Price
$49.13
Change
-$0.72 (-1.44%)
Updated
Jun 30, 02:22 PM (EDT)
Capitalization
3.95B
31 days until earnings call
Interact to see
Advertisement

MDNAF vs PTCT

Header iconMDNAF vs PTCT Comparison
Open Charts MDNAF vs PTCTBanner chart's image
Medicenna Therapeutics
Price$0.61
Change-$0.05 (-7.58%)
Volume$38.15K
Capitalization47.34M
PTC Therapeutics
Price$49.13
Change-$0.72 (-1.44%)
Volume$978
Capitalization3.95B
MDNAF vs PTCT Comparison Chart in %
Loading...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDNAF vs. PTCT commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDNAF is a Hold and PTCT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (MDNAF: $0.61 vs. PTCT: $49.84)
Brand notoriety: MDNAF and PTCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDNAF: 94% vs. PTCT: 108%
Market capitalization -- MDNAF: $47.34M vs. PTCT: $3.95B
MDNAF [@Biotechnology] is valued at $47.34M. PTCT’s [@Biotechnology] market capitalization is $3.95B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDNAF’s FA Score shows that 0 FA rating(s) are green whilePTCT’s FA Score has 1 green FA rating(s).

  • MDNAF’s FA Score: 0 green, 5 red.
  • PTCT’s FA Score: 1 green, 4 red.
According to our system of comparison, PTCT is a better buy in the long-term than MDNAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDNAF’s TA Score shows that 4 TA indicator(s) are bullish while PTCT’s TA Score has 6 bullish TA indicator(s).

  • MDNAF’s TA Score: 4 bullish, 6 bearish.
  • PTCT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PTCT is a better buy in the short-term than MDNAF.

Price Growth

MDNAF (@Biotechnology) experienced а -6.15% price change this week, while PTCT (@Biotechnology) price change was -0.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.09%. For the same industry, the average monthly price growth was +33.47%, and the average quarterly price growth was +7.39%.

Reported Earning Dates

MDNAF is expected to report earnings on Aug 08, 2025.

PTCT is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTCT($3.95B) has a higher market cap than MDNAF($47.3M). PTCT YTD gains are higher at: 10.412 vs. MDNAF (-46.725). PTCT has higher annual earnings (EBITDA): 839M vs. MDNAF (-18.65M). PTCT has more cash in the bank: 2.03B vs. MDNAF (30M). MDNAF has less debt than PTCT: MDNAF (174K) vs PTCT (390M). PTCT has higher revenues than MDNAF: PTCT (1.77B) vs MDNAF (0).
MDNAFPTCTMDNAF / PTCT
Capitalization47.3M3.95B1%
EBITDA-18.65M839M-2%
Gain YTD-46.72510.412-449%
P/E RatioN/A7.66-
Revenue01.77B-
Total Cash30M2.03B1%
Total Debt174K390M0%
FUNDAMENTALS RATINGS
MDNAF vs PTCT: Fundamental Ratings
MDNAF
PTCT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9048
P/E GROWTH RATING
1..100
10018
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDNAF's Valuation (39) in the null industry is somewhat better than the same rating for PTCT (99) in the Biotechnology industry. This means that MDNAF’s stock grew somewhat faster than PTCT’s over the last 12 months.

MDNAF's Profit vs Risk Rating (100) in the null industry is in the same range as PTCT (100) in the Biotechnology industry. This means that MDNAF’s stock grew similarly to PTCT’s over the last 12 months.

MDNAF's SMR Rating (99) in the null industry is in the same range as PTCT (100) in the Biotechnology industry. This means that MDNAF’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for MDNAF (90) in the null industry. This means that PTCT’s stock grew somewhat faster than MDNAF’s over the last 12 months.

PTCT's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for MDNAF (100) in the null industry. This means that PTCT’s stock grew significantly faster than MDNAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDNAFPTCT
RSI
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
78%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JLS18.690.13
+0.70%
Nuveen Mortgage and Income Fund
XJH41.600.22
+0.53%
iShares ESG Select Scrn S&P Mid-Cap ETF
PAAA51.450.02
+0.04%
PGIM AAA CLO ETF
GRW34.51N/A
N/A
TCW Compounders ETF
ROM74.59-0.24
-0.32%
ProShares Ultra Technology

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
-7.58%
LRMR - MDNAF
25%
Poorly correlated
-1.62%
VIR - MDNAF
25%
Poorly correlated
-2.64%
STOK - MDNAF
23%
Poorly correlated
-1.77%
CGEM - MDNAF
23%
Poorly correlated
+0.13%
PTCT - MDNAF
22%
Poorly correlated
+0.59%
More

PTCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTCT has been loosely correlated with ACLX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PTCT jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTCT
1D Price
Change %
PTCT100%
+0.59%
ACLX - PTCT
45%
Loosely correlated
+0.90%
RXRX - PTCT
44%
Loosely correlated
-6.85%
BEAM - PTCT
42%
Loosely correlated
-1.98%
IDYA - PTCT
42%
Loosely correlated
-4.13%
XNCR - PTCT
42%
Loosely correlated
-3.10%
More